Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Nova Mentis Life Science Corp. C.LIB

Nova Mentis Life Science Corp is a Canadian-based company focused on building and supporting a diversified portfolio of health and wellness businesses. Through its subsidiary, the company is focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes and providing a Health Canada Standard Licensed facility focused on the... see more

CSE:LIB - Post Discussion

View:
Post by Edcando on Apr 20, 2018 12:26pm

41.5

The quote on this site is wrong (at least on my screen). 41.5 on our way to 42 (and hopefully much higher). Let's hope we're on the Friday list for licenses
Comment by serendipidy on Apr 20, 2018 12:28pm
I see 41.5 on mine. I'm think Licence today. Perhaps wishful thinking but I'm hoping, as I've said before we have twice as good a chance as others as we've applied for 2..
Comment by LIBFREEORDIE on Apr 20, 2018 12:28pm
Agree, even if not on 4/20 it puts us another week closer in amy case.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities